DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Emory University opens first proton therapy center in Georgia 28th PT center in the U.S.

Elekta Unity MR-linac gains FDA 510(k) clearance Simultaneously delivers radiation dose and visualization of tumors

Dr. Hermann Requardt United Imaging Healthcare appoints senior scientific advisor

Patient denied proton therapy dies, family received $25 million in court Points to the need for greater treatment coverage for certain cancer patients

Microbeam radiation therapy could lead to single session treatments Healthy cells tolerate treatment while tumors lose structure

CMS to unveil mandatory payment model for radiation oncology Part of determining approach that saves more and offers greater quality

European report says radiotherapy 'undervalued' and needing 'greater investment' Equipment shortages, lack of investment, training variations

ViewRay to supply UK's GenesisCare with country's first MRIdian systems Providing soft-tissue imaging in real time and better tumor targeting

Accuray showcases software upgrades for CyberKnife and Radixact at ASTRO Allows for 40 percent faster treatment delivery

Precision cancer care with proton and radiation oncology Some of the latest systems and software entering the market

Could this mean lights-out
for cancer?

Mayo Clinic researchers discover molecular 'code' for 'turning off' cancer cells

by John W. Mitchell , Senior Correspondent
Just as you would flip a switch to turn off a light, a new discovery by Mayo Clinic scientists may point the way to shutting off the growth of cancer cells.

“We found that an adhesion protein, the glue that keeps normal cells together, suppresses cell growth through small molecules called miRNAs,” Dr. Antonis Kourtidis told HCB News. “We discovered that this structure is missing in many tumors.”

Story Continues Below Advertisement

RamSoft PowerServer™ RIS/PACS - Enabling Efficient Diagnostic Imaging

RamSoft's PowerServer™ RIS/PACS is an intuitive, single database application that enables healthcare practices to operate diagnostic imaging more efficiently than ever before.Why is this important? Click to find out.



In cultured cell experiments, loss of miRNAs results in abnormal cell growth. But when the miRNAs are restored, abnormal growth was significantly suppressed, according to Kourtidis.

Kourtidis and the other researchers think the discovery of this new, unexpected biology “provides the code, the software for turning off cancer," adding that preliminary results in aggressive breast and bladder cancer cultured cells have been encouraging.

Obviously, the practical use of these findings will take some time.

“There are still many more steps and several years down the road for an actual treatment to be developed from this discovery,” said Kourtidis. “Extensive research needs to be done in identifying the affected miRNAs in each tumor type, in preclinical models, in miRNA delivery methods and, of course, in clinical trials.”

The miRNAs orchestrate whole cellular programs by simultaneously regulating expression of a group of genes. The investigators found that when normal cells come in contact with each other, a specific subset of miRNAs suppresses genes that promote cell growth. However, when adhesion is disrupted in cancer cells, these miRNAs are misregulated and cells grow out of control.

The nuts and bolts of the study are significant, as it brings together two so far unrelated research fields – cell-to-cell adhesion and miRNA biology.

Kourtidis noted that the role of adhesion proteins in cell behavior has long baffled scientists. But now that this link has been discovered, it uncovers a new strategy for cancer therapy.

“Our findings provide a roadmap for a new approach to treatment based on these very small molecules called miRNAs,” he stressed. “However, again, it is still very early to predict how successful this will be. It is very likely this therapy would be combined with current treatments. And of course surgery may also still be necessary.”

The result of their research was published in Nature Cell Biology.

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED